Individuals at risk for severe COVID-19 in whom ritonavir-containing therapies are contraindicated or may lead to interactions with concomitant medications: a retrospective analysis of German health insurance claims data

BACKGROUND: Nirmatrelvir/ritonavir is authorized for the treatment of COVID-19 but has several contraindications and potential drug–drug interactions (pDDIs) due to ritonavir-induced irreversible inhibition of cytochrome P450 3A4. We aimed to assess the prevalence of individuals with one or more ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Lübbert, Christoph, Dykukha, Igor, Pelz, Jann-Patrick, Yearley, Helen, Junker, Wolfgang, Gruber, Nina, Escher, Sibyll, Biereth, Katrin, Melnik, Sima, Puschmann, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321469/
https://www.ncbi.nlm.nih.gov/pubmed/37415918
http://dx.doi.org/10.7573/dic.2023-3-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321469/
https://www.ncbi.nlm.nih.gov/pubmed/37415918
http://dx.doi.org/10.7573/dic.2023-3-4

Ejemplares similares